CN116898988A - Skin reprogramming factor preparation, biological material and application - Google Patents
Skin reprogramming factor preparation, biological material and application Download PDFInfo
- Publication number
- CN116898988A CN116898988A CN202311028818.XA CN202311028818A CN116898988A CN 116898988 A CN116898988 A CN 116898988A CN 202311028818 A CN202311028818 A CN 202311028818A CN 116898988 A CN116898988 A CN 116898988A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- acid molecule
- transcription factor
- molecule encoding
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 230000008672 reprogramming Effects 0.000 title claims abstract description 51
- 239000012620 biological material Substances 0.000 title claims abstract description 12
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 176
- 210000003491 skin Anatomy 0.000 claims abstract description 125
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 67
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 60
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims abstract description 27
- 101150111214 lin-28 gene Proteins 0.000 claims abstract description 27
- 108010045179 SOXB1 Transcription Factors Proteins 0.000 claims abstract description 26
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 claims abstract description 25
- 102000005635 SOXB1 Transcription Factors Human genes 0.000 claims abstract description 23
- 102000002584 Octamer Transcription Factor-3 Human genes 0.000 claims abstract description 22
- 230000003779 hair growth Effects 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 108091026890 Coding region Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000008488 polyadenylation Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 210000004927 skin cell Anatomy 0.000 claims description 7
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 6
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims description 3
- HITGTSFRKOQULY-DKZDHXMOSA-N 5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound CC1([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=NC(=O)NC1=O HITGTSFRKOQULY-DKZDHXMOSA-N 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 230000009759 skin aging Effects 0.000 abstract description 12
- 230000037303 wrinkles Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 210000003780 hair follicle Anatomy 0.000 abstract description 11
- 238000011065 in-situ storage Methods 0.000 abstract description 7
- 230000035755 proliferation Effects 0.000 abstract description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 241000254158 Lampyridae Species 0.000 description 23
- 102000034287 fluorescent proteins Human genes 0.000 description 23
- 108091006047 fluorescent proteins Proteins 0.000 description 23
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000007547 defect Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 108020005345 3' Untranslated Regions Proteins 0.000 description 10
- 108020003589 5' Untranslated Regions Proteins 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 239000001993 wax Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 230000003698 anagen phase Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012459 cleaning agent Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 4
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 101150005399 sod2 gene Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- -1 70% alcohol Chemical compound 0.000 description 2
- 108010027529 Bio-glue Proteins 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100027186 Extracellular superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000836222 Homo sapiens Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000631711 Homo sapiens Signal peptide, CUB and EGF-like domain-containing protein 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 101150106019 Mmp2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005073 RNA Cap Analogs Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100028925 Signal peptide, CUB and EGF-like domain-containing protein 3 Human genes 0.000 description 1
- 101150100931 VI gene Proteins 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- RZUBARUFLYGOGC-MTHOTQAESA-L acid fuchsin Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=C(N)C(C)=CC(C(=C\2C=C(C(=[NH2+])C=C/2)S([O-])(=O)=O)\C=2C=C(C(N)=CC=2)S([O-])(=O)=O)=C1 RZUBARUFLYGOGC-MTHOTQAESA-L 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003661 hair follicle regeneration Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Manufacturing & Machinery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The skin reprogramming factor preparation, the biological material and the application provided by the embodiment of the application comprise 2-4 mole parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 mole part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 mole part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 mole part of mRNA nucleic acid molecule encoding Glis1 transcription factor and 1 mole part of mRNA nucleic acid molecule encoding Lin28 transcription factor; after the skin reprogramming factor preparation is introduced into skin, the skin aging is reversed in situ, so that the expression of the skin aging-related genes is regulated down, the skin wrinkle eliminating effect is better, and meanwhile, the hair follicle-related genes are regulated up, so that the hair follicle proliferation and hair growth can be promoted.
Description
Technical Field
The application relates to the technical field of biological medicine, in particular to a skin reprogramming factor preparation, a biological material and application.
Background
Skin aging is manifested as: gradual loss of elasticity and reduced collagen content of the skin, leading to skin sagging and the formation of wrinkles and fine lines, especially in the forehead, corners of the eyes and neck of the face; at the same time, wrinkles are also created by muscle contraction caused by repetitive facial expressions.
Currently, botulinum toxin injections are currently the primary non-surgical method of eliminating wrinkles, which works well for eliminating skin expression wrinkles, but suffer from the disadvantage that the effect is temporary, lasting on average about 3-4 months, and the patient needs to receive injections periodically to maintain a smooth and youthful appearance of the skin, and wrinkles reappear if injections are not performed periodically. At the same time, repeated injections of botulinum toxin induce an immune response in the body, resulting in inefficiency.
Hundreds of millions of men, women and even children worldwide are afflicted with alopecia, the cause of which is numerous, such as inheritance, aging, labor, cancer treatment, burns and stress. Although hair loss does not cause serious health problems, it can bring emotional burden, trauma and even depression because it can permanently change the personal image.
At present, methods for treating alopecia are very limited, mainly comprise methods of drug treatment (minoxidil and finasteride), surgical treatment (hair implantation), physical therapy (traditional Chinese medicine acupuncture and low-frequency laser therapy) and the like, can not prevent alopecia for a long time, and can not realize hair follicle regeneration.
Disclosure of Invention
In view of the above problems, embodiments of the present application provide a skin reprogramming factor preparation, a biomaterial and use thereof, so as to solve the above technical problems.
In a first aspect, embodiments of the present application provide a skin reprogramming factor formulation comprising 2 to 4 molar parts of an mRNA nucleic acid molecule encoding an Oct4 transcription factor, 1 molar part of an mRNA nucleic acid molecule encoding a Sox2 transcription factor, 1 molar part of an mRNA nucleic acid molecule encoding a Klf4 transcription factor, 1 molar part of an mRNA nucleic acid molecule encoding a Glis1 transcription factor, and 1 molar part of an mRNA nucleic acid molecule encoding a Lin28 transcription factor.
Alternatively, the skin reprogramming factor formulation comprises 3 molar parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Glis1 transcription factor, and 1 molar part of mRNA nucleic acid molecule encoding Lin28 transcription factor.
Optionally, the skin reprogramming factor preparation further comprises a first solvent, wherein the concentration of citrate in the first solvent is 8-12 mmol/L, and the concentration of sodium chloride in the first solvent is 120-140 mmol/L.
Optionally, the concentration of citrate in the first solvent is 10mmol/L, the concentration of sodium chloride in the first solvent is 130mmol/L, and the pH value of the first solvent is 7.5.
Alternatively, each of the mRNA nucleic acid molecules includes a 5' cap structure, a 5' utr sequence, an mRNA coding sequence for a transcription factor, a 3' utr sequence, and a polyadenylation sequence.
Optionally, some or all of the nucleotides in the mRNA nucleic acid molecule encoding the Oct4 transcription factor, the mRNA nucleic acid molecule encoding the Sox2 transcription factor, the mRNA nucleic acid molecule encoding the Klf4 transcription factor, the mRNA nucleic acid molecule encoding the Glis1 transcription factor, and the mRNA nucleic acid molecule encoding the Lin28 transcription factor are chemically modified to increase the stability of the mRNA nucleic acid molecule in vivo.
Alternatively, the chemical modification comprises replacing 100% of the cytosines in the mRNA nucleic acid molecule encoding the Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor with 5-methylpseudouridine, and replacing 100% of the uracils in the mRNA nucleic acid molecule encoding Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor with N1-methylpseudouridine.
In a second aspect, embodiments of the present application provide a biomaterial that is a host skin cell comprising a skin reprogramming factor formulation as described above.
In a third aspect, embodiments of the present application provide an application of the skin reprogramming factor preparation or the biological material in preparing a skin cell reprogramming agent.
In a fourth aspect, the present application provides an application of the skin reprogramming factor preparation or the biological material in preparing skin anti-aging drugs or hair growth drugs.
The skin reprogramming factor preparation, the biological material and the application provided by the embodiment of the application comprise 2-4 mole parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 mole part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 mole part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 mole part of mRNA nucleic acid molecule encoding Glis1 transcription factor and 1 mole part of mRNA nucleic acid molecule encoding Lin28 transcription factor; after the skin reprogramming factor preparation is introduced into skin, the skin aging is reversed in situ, so that the expression of the skin aging-related genes is regulated down, the skin wrinkle eliminating effect is better, and meanwhile, the hair follicle-related genes are regulated up, so that the hair follicle proliferation and hair growth can be promoted.
These and other aspects of the application will be more readily apparent from the following description of the embodiments.
Drawings
FIG. 1 is a graph showing the results of the fluorescence test of human in vitro skin in example 2 of the present application.
FIG. 2 is a graph showing the results of the in vitro skin injection experiment of human in example 3 of the present application.
FIG. 3 is a graph showing the results of skin injection experiments of skin defect models after skin transplantation of immunodeficient mice in example 4 of the present application.
Fig. 4 shows the results of skin injection experiments of different formulations of the skin reprogramming factor preparation in example 5 of the present application.
Detailed Description
Embodiments of the present application are described in detail below, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to like or similar elements or elements having like or similar functions throughout. The embodiments described below by referring to the drawings are exemplary only for explaining the present application and are not to be construed as limiting the present application.
In order to enable those skilled in the art to better understand the solution of the present application, the following description will make clear and complete descriptions of the technical solution of the present application in the embodiments of the present application with reference to the accompanying drawings. It will be apparent that the described embodiments are only some, but not all, embodiments of the application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
In the embodiments of the present application, it should be noted that, in this document, relational terms such as first and second, and the like are used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions.
In describing embodiments of the present application, words such as "exemplary" or "such as" are used to mean illustrated, described, or described. Any embodiment or design described as "exemplary" or "such as" in an embodiment of the application is not necessarily to be construed as preferred or advantageous over another embodiment or design. The use of words such as "example" or "such as" is intended to present relative concepts in a clear manner.
In addition, the term "plurality" in the embodiments of the present application means two or more, and in view of this, the term "plurality" may be understood as "at least two" in the embodiments of the present application. "at least one" may be understood as one or more, for example as one, two or more. For example, including at least one means including one, two or more, and not limiting what is included, e.g., including at least one of A, B and C, then A, B, C, A and B, A and C, B and C, or A and B and C, may be included.
It should be noted that, in the embodiment of the present application, "and/or" describe the association relationship of the association object, which means that three relationships may exist, for example, a and/or B may be represented: a exists alone, A and B exist together, and B exists alone. The character "/", unless otherwise specified, generally indicates that the associated object is an "or" relationship.
The experimental methods in the following examples are conventional methods unless otherwise specified.
Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
An embodiment of the present application provides a skin reprogramming factor formulation comprising 2 to 4 molar parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Glis1 transcription factor, and 1 molar part of mRNA nucleic acid molecule encoding Lin28 transcription factor.
In this example, by adjusting the molar ratio of mRNA nucleic acid molecules expressing different transcription factors, a specific skin reprogramming factor preparation is formed, and after the preparation is introduced into the skin, the skin aging is reversed in situ, so that the expression of the skin aging-related gene is down-regulated, and the skin wrinkle eliminating effect is better, and meanwhile, the hair follicle-related gene is up-regulated, so that the hair follicle proliferation and hair growth can be promoted.
As one embodiment, the skin reprogramming factor formulation of the present example comprises 3 molar parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Glis1 transcription factor, and 1 molar part of mRNA nucleic acid molecule encoding Lin28 transcription factor.
As an embodiment, the skin reprogramming factor preparation of the present example further comprises a first solvent, and the mRNA nucleic acid molecule encoding Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor described above are dissolved in the first solvent. The first solvent can be formed by citrate and normal saline, the concentration of the citrate in the first solvent is 8-12 mmol/L, and the concentration of the sodium chloride in the first solvent is 120-140 mmol/L.
In this embodiment, each mRNA nucleic acid molecule can be made less susceptible to degradation by the first solvent.
In some embodiments, the concentration of citrate in the first solvent is 10mmol/L, the concentration of sodium chloride in the first solvent is 130mmol/L, and the pH of the first solvent is 7.5.
As one embodiment, each of the mRNA nucleic acid molecules includes a 5' cap structure, a 5' utr sequence, an mRNA coding sequence for a corresponding transcription factor, a 3' utr sequence, and a polyadenylation sequence.
Specifically, mRNA nucleic acid molecules encoding Oct4 transcription factors include a 5' cap structure, a 5' utr sequence, an mRNA coding sequence for Oct4 transcription factors, a 3' utr sequence, and a polyadenylation sequence; mRNA nucleic acid molecules encoding Sox2 transcription factors include 5' cap structure, 5' UTR sequence, mRNA coding sequence for Sox2 transcription factor, 3' UTR sequence and polyadenylation sequence; mRNA nucleic acid molecules encoding the Klf4 transcription factor include 5' cap structure, 5' UTR sequence, mRNA coding sequence for the Klf4 transcription factor, 3' UTR sequence, and polyadenylation sequence; mRNA nucleic acid molecules encoding the Glis1 transcription factor include 5' cap structure, 5' UTR sequence, mRNA coding sequence for the Glis1 transcription factor, 3' UTR sequence and polyadenylation sequence; mRNA nucleic acid molecules encoding the Lin28 transcription factor include 5' cap structure, 5' UTR sequence, mRNA coding sequence for the Lin28 transcription factor, 3' UTR sequence, and polyadenylation sequence.
As one embodiment, a part or all of the nucleotides in the mRNA nucleic acid molecule encoding the Oct4 transcription factor, the mRNA nucleic acid molecule encoding the Sox2 transcription factor, the mRNA nucleic acid molecule encoding the Klf4 transcription factor, the mRNA nucleic acid molecule encoding the Glis1 transcription factor, and the mRNA nucleic acid molecule encoding the Lin28 transcription factor are chemically modified to improve the stability of the mRNA nucleic acid molecule in vivo.
In some embodiments, the chemical modification comprises replacing 100% of the cytosines in the mRNA nucleic acid molecule encoding the Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor with 5-methylpseudouridine, and replacing 100% of the uracils in the mRNA nucleic acid molecule encoding Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor with N1-methylpseudouridine.
Example 1: preparation of skin reprogramming factor preparation
The skin reprogramming factor formulation of the present example can be prepared as follows:
s11, preparation of DNA templates of transcription factors
The Oct4 transcription factor DNA template comprises a T7 promoter shown as SEQ ID NO.10, a 5'UTR DNA sequence shown as SEQ ID NO.1, an Oct4 transcription factor DNA sequence shown as SEQ ID NO.3 and a 3' UTR DNA sequence shown as SEQ ID NO. 2;
the Sox2 transcription factor DNA template comprises a T7 promoter shown as SEQ ID NO.10, a 5'UTR DNA sequence shown as SEQ ID NO.1, a Sox2 transcription factor DNA sequence shown as SEQ ID NO.4 and a 3' UTR DNA sequence shown as SEQ ID NO. 2;
the Klf4 transcription factor DNA template comprises a T7 promoter shown as SEQ ID NO.10, a 5'UTR DNA sequence shown as SEQ ID NO.1, a Klf4 transcription factor DNA sequence shown as SEQ ID NO.5 and a 3' UTR DNA sequence shown as SEQ ID NO. 2;
the Glis1 transcription factor DNA template comprises a T7 promoter shown as SEQ ID NO.10, a 5'UTR DNA sequence shown as SEQ ID NO.1, a Glis1 transcription factor DNA sequence shown as SEQ ID NO.6 and a 3' UTR DNA sequence shown as SEQ ID NO. 2;
the Lin28 transcription factor DNA template comprises a T7 promoter shown as SEQ ID NO.10, a 5'UTR DNA sequence shown as SEQ ID NO.1, a Lin28 transcription factor DNA sequence shown as SEQ ID NO.7 and a 3' UTR DNA sequence shown as SEQ ID NO. 2;
DNA templates for transcription factors were synthesized based on the above sequence information and can be directly ordered by IDT company in U.S.A.
S12, preparation of DNA full templates of transcription factors
And adding poly- (a) tails on the Oct4 transcription factor DNA template, the Sox2 transcription factor DNA template, the Klf4 transcription factor DNA template, the Glis1 transcription factor DNA template and the Lin28 transcription factor DNA template by PCR to obtain an Oct4 transcription factor DNA full template, a Sox2 transcription factor DNA full template, a Klf4 transcription factor DNA full template, a Glis1 transcription factor DNA full template and a Lin28 transcription factor DNA full template respectively.
PCR premix (total volume 200. Mu.l, eight reactions 25. Mu.l each) was prepared according to Table 1
TABLE 1 composition of PCR premix
| Component (A) | Dosage of | Final concentration |
| Kapa PCR mix(2X) | 100μL | 1X |
| Tailing primer-F1 μm | 6μL | 0.3μM |
| Tailing primer-T120 [ mu ] m | 6μL | 0.3μM |
| Water and its preparation method | 80μL | |
| gBlock DNA 10μg/μl | 8μL | 40-400pg/μl |
Wherein, the tailing primer-F1 is shown as SEQ ID NO.11, and the tailing primer-T120 is shown as SEQ ID NO. 9.
PCR was performed using the conditions of table 2:
TABLE 2 tailing PCR conditions
| Number of cycles | Denaturation (denaturation) | Annealing | Expansion of |
| 1 | 95℃,2–3min | ||
| 2-31 | 98℃,20s | 60℃,15s | 72℃,60s |
| 32 | 72℃,3min |
The quality of the PCR products was checked by gel electrophoresis.
Cut gel recovery PCR product (QIAquick PCR purification kit, qiagen, cat.no. 28106): the final concentration of the tail template was adjusted to 100 ng/. Mu.l as the whole template for each transcription factor DNA.
S13, in vitro transcription synthesis of mRNA nucleic acid molecules of transcription factors
13-1, mRNA cap structure and nucleotide mixture were assembled according to Table 3:
hat Structure N7mGpppGm RNA cap analog (New England Biolabs), methyl-5' -triphosphates (Me-CTP; trilink) 100% replaced CTP, N1-methyl pseudoudidine (Me-Pseudo-UTP; trilink), and 100% replaced UTP the other components were all from MEGAscript T7 kit (Ambion).
TABLE 3mRNA cap structures and nucleotide mixtures
13-2, an mRNA in vitro transcription system was assembled according to Table 4:
TABLE 3 in vitro mRNA transcription System
13-3, the reaction is placed in a PCR instrument and incubated for 3-6 h at 37 ℃.
13-4, 2. Mu.l of Turbo DNase (from MEGAscript T7 kit, ambion, cat. No. AM1334) was added to each sample.
13-5, gently mix and incubate at 37℃for 15min.
13-6, purifying the DNase-treated reaction using a MEGAclear kit (Ambion, cat.no. AM1908); the modified mRNA was eluted with a total of 100. Mu.l of elution buffer (50. Mu.l of elution buffer was eluted twice).
13-7, the purified mRNA nucleic acid molecules of the respective transcription factors were treated with phosphatase (Antarctic phosphatase (New England Biolabs, cat.no. M0289S).
13-8, to each sample (. About.100. Mu.l) 11. Mu.l of 10 Xphosphatase buffer was added followed by 2. Mu.l of phosphatase; the samples were gently mixed and incubated at 37℃for 0.5-1 h.
13-9, after elution, the concentration of modified mRNA was measured in a NanoDrop spectrophotometer. The expected total yield should be-50 ug (30-70 ug range; 100 ul elution volume of one 40 ul IVT reaction is 300-700 ng ul).
13-10, mRNA nucleic acid molecule encoding Oct4 transcription factor, mRNA nucleic acid molecule encoding Sox2 transcription factor, mRNA nucleic acid molecule encoding Klf4 transcription factor, mRNA nucleic acid molecule encoding Glis1 transcription factor, and mRNA nucleic acid molecule encoding Lin28 transcription factor at a molar ratio of 3:1:1:1:1:1, by addition of citric acid-normal saline (10 mmol/L citrate, 130mmol/L sodium chloride, nuclease-free distilled water, PH 7.5) to form a skin reprogramming factor formulation, the concentration was adjusted to 100ng/μl.
Example 2: verification of the intradermal injection of the mRNA preparation encoding firefly fluorescent protein
An mRNA nucleic acid molecule encoding a firefly fluorescent protein was prepared according to the method of example 1, the firefly fluorescent protein whole DNA template comprising a T7 promoter as shown in SEQ ID No.10, a 5'utr DNA sequence as shown in SEQ ID No.1, a firefly fluorescent protein DNA sequence as shown in SEQ ID No.8, a 3' utr DNA sequence as shown in SEQ ID No.2, and a poly- (a) tail; and then carrying out in vitro transcription on the whole DNA template of the firefly fluorescent protein to obtain an mRNA nucleic acid molecule for encoding the firefly fluorescent protein.
mRNA nucleic acid molecules encoding the firefly fluorescent protein were dissolved in citrate-normal saline (10 mmol/L citrate, 130mmol/L sodium chloride, nuclease free distilled water, pH 7.5) to form mRNA preparations encoding the firefly fluorescent protein.
The expression of the mRNA preparation encoding the firefly fluorescent protein is quantitatively detected by an IVIS imager by injecting the mRNA preparation encoding the firefly fluorescent protein into human isolated skin, and the specific steps are as follows: the volunteer operation incision redundant whole skin is transported to a laboratory, after washing with normal saline, adipose tissues are removed by using dissecting scissors, epidermis and dermis are reserved, the skin is cultured in a 10% fetal bovine serum DEME culture medium and a 5% CO2 cell incubator to form a human isolated skin culture model, an mRNA preparation encoding firefly fluorescent protein is injected intradermally, the injection part is the junction of the epidermis and the dermis, after 6 hours, a firefly fluorescent protein substrate is added, and the fluorescence intensity of the firefly fluorescent protein is detected in an IVIS in-vitro in-vivo imager.
Example 3: intradermal injection verification of skin reprogramming factor formulations
The skin reprogramming factor preparation prepared in example 1 was injected into human ex vivo skin (preparation of human ex vivo skin is described in example 2) to reverse skin aging in situ, and quantitative PCR assays were performed on aging index P16, skin epigenetic index H3K9me3, skin cell proliferation index K67, skin collagens I and VI, extracellular matrices MMP1 and MMP9, and oxygen radical SOD3 after collecting skin tissue with the empty mRNA preparation and the mRNA preparation encoding firefly fluorescent protein of example 2, respectively, as follows:
after collection, total mRNA was extracted by Trizol method and SuperScript was prepared according to In Vitrogen Co., ltd TM IV One-Step RT-PCR System Specification One-Step reverse transcription PCR was performed, and a One-Step reverse transcription PCR reaction System was prepared by SybrGreen method, inThe ABIQuantum studio 5 quantitative PCR instrument reacted to process data in double delta and output quantitative gene expression data.
Example 4: skin defect model establishment and skin reprogramming factor preparation skin injection experiment after skin transplantation of human in-vitro skin-immunodeficiency mice
As a comparison, a SCUB3mRNA preparation and a reporter mRNA preparation were used, wherein the SCUB3mRNA preparation and the reporter mRNA preparation were prepared in the same manner as in example 1.
The SCUB3-DNA template comprises a T7 promoter shown as SEQ ID NO.10, a 5'UTR DNA sequence shown as SEQ ID NO.1, a DNA sequence encoding SCUB3, a 3' UTR DNA sequence shown as SEQ ID NO.2 and a poly- (a) tail; and then carrying out in vitro transcription on the SCUB3-DNA template to obtain the mRNA nucleic acid molecule encoding the SCUB 3. The mRNA nucleic acid molecule encoding SCUB3 was dissolved in citrate-normal saline (10 mmol/L citrate, 130mmol/L sodium chloride, nuclease free distilled water, pH 7.5) to form a preparation of SCUB3 mRNA.
An mRNA nucleic acid molecule encoding a firefly fluorescent protein was prepared according to the method of example 1, the firefly fluorescent protein whole DNA template comprising a T7 promoter as shown in SEQ ID No.10, a 5'utr DNA sequence as shown in SEQ ID No.1, a firefly fluorescent protein DNA sequence as shown in SEQ ID No.8, a 3' utr DNA sequence as shown in SEQ ID No.2, and a poly- (a) tail; and then carrying out in vitro transcription on the whole DNA template of the firefly fluorescent protein to obtain an mRNA nucleic acid molecule for encoding the firefly fluorescent protein. mRNA nucleic acid molecules encoding the firefly fluorescent protein were dissolved in citrate-normal saline (10 mmol/L citrate, 130mmol/L sodium chloride, nuclease free distilled water, pH 7.5) to form mRNA preparations encoding the firefly fluorescent protein.
Skin injections were performed separately using the skin reprogramming factor formulation of example 1, the SCUB3mRNA formulation, the Luc mRNA formulation (the mRNA formulation encoding firefly fluorescent protein of example 2) to reverse skin aging in situ, promote skin repair in humans, and evaluate the effects, as follows:
first, human ex vivo skin-immunodeficiency mice skin following skin transplantation skin defect model establishment: NOD-Prkdcsccid/Smoc immunodeficient mice were purchased from the corresponding biological company and the health status and immunodeficient properties of the mice were determined prior to the start of the experiment.
Donor skin extraction: skin tissue surgically removed from the volunteer's body is taken as donor skin and strict aseptic procedures are followed during surgery to reduce the risk of infection.
Trimming donor skin: fat and other tissues were removed and the extracted skin tissue was trimmed to the appropriate 2X2 cm skin to accommodate the skin defect area of the mice. Treating the skin pieces may include washing, hair and adipose tissue removal steps to ensure the purity of the graft.
Preparation of mice: immunodeficient mice were anesthetized and local disinfection was done at the target skin defect area. Ensuring that the mice are in a painless and comfortable state.
Transplanting skin: the treated skin pieces were carefully placed on the skin defect areas of the mice. The skin pieces were fixed to the defect area using sutures or bio-glue, etc., and lesions of about 1 mm were formed on the isolated skin of the human body, covered with sterile dressing, observed periodically and sampled at the corresponding time points.
Second, HE staining:
firstly, obtaining a tissue slice fixed and embedded by 4% PFA, and finally obtaining the slice through dehydration and embedding; dewaxing and dehydrating: the slices of the wax block were immersed in a dewaxing agent Xylene to remove waxes.
Washing: the dewaxed slice is washed under running tap water to thoroughly remove the dewaxed agent residue.
Dyeing: the sections are sequentially immersed in a stain, first a heme stain (hemadyloxy) which stains the cell nucleus and the material surrounding the cell nucleus. The sections were then transferred to an acid wine red (Eosin) solution, which stained the cytosol and extracellular matrix.
Dehydrating: the stained sections were sequentially immersed in different concentrations of alcohol (e.g., 70% alcohol, 95% alcohol, and absolute alcohol) to dehydrate the sections.
And (3) cleaning agent treatment: the slices are immersed in a suitable cleaning agent, such as Xylene or other cleaning agent, to remove alcohol and make the slices transparent.
Sealing piece: the sections are placed in a suitable Medium, such as a clear coverslip (e.g., a moving Medium) between a glass slide and a cover slip, and then covered with a glass slide cover slip.
After the above steps are completed, the slice is ready. Using a microscope, the staining of the nuclei (blue or purple), the staining of the cytosol and extracellular matrix (pink), and details of skin tissue structure such as anagen hair follicles can be observed by HE-stained sections, quantification of the thickness of the epidermis and anagen hair follicles is performed with Image J software, and statistical and data output is performed with graphpad prism software.
Third, mass staining:
first, it is necessary to obtain tissue sections, dehydrated and embedded by 4% pfa fixation and embedding process, and finally obtain sections, dehydrated by wax removal: the slices of the wax block were immersed in an Xylene dewaxing agent to remove wax. Washing: the dewaxed slice is washed under running tap water to thoroughly remove the dewaxed agent residue.
Dyeing with an acidic dye: the sections are immersed in an acidic stain (e.g., acid magenta) for staining the cytoplasm and nucleus. The time of soaking in the stain was performed according to the standard procedure of the laboratory. Washing: the stained sections were washed under running tap water to remove excess stain.
Cobalt acid staining: the sections were immersed in a staining agent containing cobalt acid for staining the collagen fibers. The cobalt acid dye is a blue dye which can make the collagen fiber blue. Washing: the stained sections were washed under running tap water to remove excess stain. Acid washing: the slices are immersed in a dilute acidic detergent (e.g., acetic acid) for removal of the cobalt acid residue.
Blue dyeing: the sections were immersed in a stain containing hematoxylin and hematoxylin blue. Hematoxylin blue is a blue dye used to stain nuclei. Washing: the stained sections were washed under running tap water to remove excess stain. Dehydrating: the sections were sequentially immersed in different concentrations of alcohol (e.g., 70% alcohol, 95% alcohol, and absolute alcohol) to dehydrate the sections. And (3) cleaning agent treatment: the slices are immersed in a suitable cleaning agent, such as Xylene or other cleaning agent, to remove alcohol and make the slices transparent.
Sealing piece: the sections are placed in a suitable Medium, such as a clear coverslip (e.g., a moving Medium) between a glass slide and a cover slip, and then covered with a glass slide cover slip.
After the above steps are completed, the sections are ready for observation. Using a microscope, the staining of collagen fibers (blue) and the staining of nuclei (purple), as well as details of tissue structure, can be observed by Masson-stained sections, image J software quantification.
Immunohistochemistry: (a) obtaining a tissue slice: first, it is necessary to obtain a tissue section dehydrated and embedded by 4% pfa fixation and embedding process, and finally obtain a section. (b) wax block treatment: the slices of the wax block were immersed in a dewaxing agent to remove wax with Xylene. (c) antigen retrieval: heat treatment was used to restore antigen activity in the sections. (d) protein blocking: to reduce non-specific binding, it is desirable to block non-specific binding sites in tissue sections, using bovine serum albumin, which is coated on the sections. (e) incubation of antibodies: the target antibody anti-Oct 4 antibody (R & D system) solution was added dropwise to the sections, and then incubated at 4 degrees overnight to allow specific binding of the antibody to Oct4 protein in the sections. (f) washing: after incubation of the antibodies, multiple washes with buffer or PBS or the like are performed to remove unbound antibodies and other non-specific binders. (g) incubation of secondary antibody: the corresponding specific secondary antibodies (R & D systems) were incubated with the sections at 4℃overnight. (h) washing: after incubation of the secondary antibody, multiple washes with buffer or PBS or the like are performed to remove unbound secondary antibody and other non-specific binders. (i) visual staining: enzyme substrates were added to the sections using enzyme-labeled horseradish peroxidase, depending on the type of secondary antibody, resulting in a visible staining reaction. (j) washing and sealing: finally, a final washing step is carried out to remove excess dyeing substances and substrates. The sections are then placed in a suitable Medium, such as a clear coverslip (e.g., a mount Medium) between a glass slide and a cover slip, and then covered with a glass slide cover slip. (k) After this step, the sections were ready for observation, using a microscope, for determining the distribution and localization of Oct4, as well as other specific structures that bind specifically to the antibody.
Example 5: skin injection experiment of skin reprogramming factor preparations with different proportions
The present example is divided into the following four experimental groups:
experiment group 1 is reporter gene chemically modified mRNA: the formulation of example 2 was used;
experiment group 2 was OSKGL (3:1:1:1:1) chemically modified mRNA: the formulation of example 1 was used;
experiment group 3 was OSKGL (1:1:1:1:1) chemically modified mRNA: the molar ratio of the mRNA nucleic acid molecule encoding the Oct4 transcription factor, the mRNA nucleic acid molecule encoding the Sox2 transcription factor, the mRNA nucleic acid molecule encoding the Klf4 transcription factor, the mRNA nucleic acid molecule encoding the Glis1 transcription factor, and the mRNA nucleic acid molecule encoding the Lin28 transcription factor was 1:1:1:1, and the concentration was adjusted to 100 ng/. Mu.l by adding citric acid-physiological saline (10 mmol/L citrate, 130mmol/L sodium chloride, nuclease-free distilled water, pH 7.5) to form a skin reprogramming factor preparation.
Experiment group 4 was OSKGL (0.5:1:1:1:1) chemically modified mRNA: the molar ratio of the mRNA nucleic acid molecule encoding the Oct4 transcription factor, the mRNA nucleic acid molecule encoding the Sox2 transcription factor, the mRNA nucleic acid molecule encoding the Klf4 transcription factor, the mRNA nucleic acid molecule encoding the Glis1 transcription factor, and the mRNA nucleic acid molecule encoding the Lin28 transcription factor was 0.5:1:1:1 by adding citric acid-physiological saline (10 mmol/L citrate, 130mmol/L sodium chloride, nuclease-free distilled water, pH 7.5) to form a skin reprogramming factor preparation, and the concentration was adjusted to 100 ng/. Mu.l.
The method comprises the following specific steps of performing intradermal injection by adopting an experimental group 1, an experimental group 2, an experimental group 3 and an experimental group 4 respectively to reverse skin aging in situ, promote skin repair of a human body and evaluate the effect:
first, human ex vivo skin-immunodeficiency mice skin following skin transplantation skin defect model establishment: NOD-Prkdcsccid/Smoc immunodeficient mice were purchased from the corresponding biological company and the health status and immunodeficient properties of the mice were determined prior to the start of the experiment.
Donor skin extraction: skin tissue surgically removed from the volunteer's body is taken as donor skin and strict aseptic procedures are followed during surgery to reduce the risk of infection.
Trimming donor skin: fat and other tissues were removed and the extracted skin tissue was trimmed to the appropriate 2X2 cm skin to accommodate the skin defect area of the mice. Treating the skin pieces may include washing, hair and adipose tissue removal steps to ensure the purity of the graft.
Preparation of mice: immunodeficient mice were anesthetized and local disinfection was done at the target skin defect area. Ensuring that the mice are in a painless and comfortable state.
Transplanting skin: the treated skin pieces were carefully placed on the skin defect areas of the mice. The skin pieces were fixed to the defect area using sutures or bio-glue, etc., covered with sterile dressing, periodically observed and sampled at the corresponding time points.
Different mRNA formulation injections: four different treatment modes, namely experiment group 1, experiment group 2, experiment group 3 and experiment group 4, are injected into the transplanted human skin, sampling is carried out 10 days after injection, and quantitative PCR (polymerase chain reaction) of senescence index P16 gene, epigenetic index H3K9me3 gene, wrinkle index collagen VI gene, wrinkle metalloprotease gene and oxygen radical index SOD2 gene is carried out.
Example 2 experimental results:
referring to fig. 1, a portion a in fig. 1 is an in vitro culture schematic of the isolated skin, and a portion B in fig. 1 is an in vitro culture schematic of the isolated skin; part C of FIG. 1 shows that the firefly luciferin mRNA preparation can be efficiently expressed within 6 hours of intradermal injection.
Example 3 experimental results:
as shown in FIG. 2, the expression of each of the empty mRNA preparation (NC), the mRNA preparation encoding firefly fluorescent protein (Luc mRNA), the skin reprogramming factor preparation (OSKGL mRNA1 and OSKGL mRNA2, respectively, were the preparation of example 1) after 5 days of reprogramming of the human skin portion, and it was found that the aging index P16 gene expression of the skin tissue was down-regulated (A), the epigenetic younger index H3K9me3 gene expression was down-regulated (B), the cell proliferation index K67 expression was up-regulated (C), the collagen I and collagen VI were up-regulated (D), the extracellular matrix MMP1, the MMP2 gene expression was down-regulated (E), and the oxygen radical index SOD2 gene expression was down-regulated (F).
Example 4 experimental results:
as shown in fig. 3, a: on a human skin graft model, immunohistochemical detection suggests that the reprogramming factor OSKGL mRNA formulation of example 1 can be efficiently expressed in the whole layer of skin after 6 hours of injection, and the expression is localized to the skin part. B: on human skin graft models, HE and Masson fiber staining typically results suggest that injection of the reprogramming factor OSKGL mRNA formulation of example 1 can reprogram the full-thickness driving portion of the skin, increasing the thickness of the epidermis. C: quantitative determination by Image J software: the reprogramming factor OSKGL mRNA of example 1 increased the thickness of the epidermis and eliminated wrinkles compared to the empty mRNA preparations, firefly luciferin mRNA preparation and SCUBE3mRNA preparation. Quantitative determination by pathological section and Image J software: while firefly luciferin mRNA preparation and SCUBE3mRNA preparation significantly increased the number of anagen follicles to promote hair growth compared to the empty mRNA preparation, the reprogramming factor OSKGL mRNA preparation of example 1 more significantly increased the number of anagen follicles to promote hair growth compared to the SCUBE3mRNA preparation.
Example 5 experimental results:
as shown in fig. 4, the specific molar ratio of the reprogrammed OSKGL factor is 3:1:1:1:1 mRNA preparation versus reporter mRNA preparation, reprogramming OSKGL factor specific molar ratio is 1:1:1:1:1, reprogramming OSKGL factor specific molar ratio of 0.5: the mRNA preparation of 1:1:1:1 can obviously reduce the aging index P16 gene, obviously reduce the metalloproteinase gene of extracellular matrix, obviously reduce the oxygen radical index SOD2 gene, obviously improve the expression of the epigenetic young index H3K9me3 gene and obviously improve the expression of the skin collagen index collagen V I gene.
The skin reprogramming factor preparation prepared by the embodiment of the application can efficiently influence the expression mode of the whole skin gene, activate the related gene network of the skin stem cells, realize the function reset of the whole skin cells, reverse skin aging in situ, reconstruct the young state of the skin, recombine the functions of the whole skin cells, increase the collagen fibers of the skin, reduce the content of oxygen free radicals, rejuvenate the epigenetic markers and lower the related genes of the aging, and the overall effect can provide a safer and more effective method for eliminating wrinkles.
The skin reprogramming factor preparation prepared by the embodiment of the application can reverse skin aging in situ on skin, the hair follicle related genes are up-regulated, the number of hair follicles in anagen phase is obviously increased, and the effects of promoting hair growth and/or improving the curative effect of hair implantation surgery and/or accidentally improving the effect of chemically modifying mRNA of SCUBE3 protein (hair follicle growth promoting gene) to increase the number of hair follicles in anagen phase and promote hair growth can be improved.
While the application has been described with respect to the above embodiments, it should be noted that modifications can be made by those skilled in the art without departing from the inventive concept, and these are all within the scope of the application.
Claims (10)
1. A skin reprogramming factor formulation comprising 2 to 4 molar parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Glis1 transcription factor, and 1 molar part of mRNA nucleic acid molecule encoding Lin28 transcription factor.
2. The skin reprogramming factor formulation of claim 1, comprising 3 molar parts of mRNA nucleic acid molecule encoding Oct4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Sox2 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Klf4 transcription factor, 1 molar part of mRNA nucleic acid molecule encoding Glis1 transcription factor, and 1 molar part of mRNA nucleic acid molecule encoding Lin28 transcription factor.
3. The skin reprogramming factor formulation of claim 1, further comprising a first solvent, wherein the concentration of citrate in the first solvent is 8 to 12mmol/L and the concentration of sodium chloride in the first solvent is 120 to 140mmol/L.
4. A skin reprogramming factor formulation as claimed in claim 3, wherein the concentration of citrate in the first solvent is 10mmol/L, the concentration of sodium chloride in the first solvent is 130mmol/L, and the pH of the first solvent is 7.5.
5. The skin reprogramming factor formulation of claim 1, wherein each of the mRNA nucleic acid molecules comprises a 5' cap structure, a 5' utr sequence, an mRNA coding sequence for a corresponding transcription factor, a 3' utr sequence, and a polyadenylation sequence.
6. The skin reprogramming factor formulation of claim 1, wherein some or all of the nucleotides in the mRNA nucleic acid molecule encoding Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor are chemically modified to increase the stability of the mRNA nucleic acid molecule in vivo.
7. The skin reprogramming factor formulation of claim 6, wherein the chemical modification comprises replacing 100% of cytosine in the mRNA nucleic acid molecule encoding Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor with 5-methylpseudouridine, and replacing 100% of uracil in the mRNA nucleic acid molecule encoding Oct4 transcription factor, the mRNA nucleic acid molecule encoding Sox2 transcription factor, the mRNA nucleic acid molecule encoding Klf4 transcription factor, the mRNA nucleic acid molecule encoding Glis1 transcription factor, and the mRNA nucleic acid molecule encoding Lin28 transcription factor with N1-methylpseudouridine.
8. A biomaterial, characterized in that it is a host skin cell comprising a skin reprogramming factor formulation as claimed in any one of claims 1 to 7.
9. Use of a skin reprogramming factor formulation of any of claims 1 to 7 or a biomaterial of claim 8 in the preparation of a skin cell reprogramming agent.
10. Use of a skin reprogramming factor formulation according to any of claims 1 to 7 or a biomaterial according to claim 8 in the manufacture of a skin anti-ageing medicament or a hair growth medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311028818.XA CN116898988A (en) | 2023-08-15 | 2023-08-15 | Skin reprogramming factor preparation, biological material and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311028818.XA CN116898988A (en) | 2023-08-15 | 2023-08-15 | Skin reprogramming factor preparation, biological material and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116898988A true CN116898988A (en) | 2023-10-20 |
Family
ID=88358309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311028818.XA Pending CN116898988A (en) | 2023-08-15 | 2023-08-15 | Skin reprogramming factor preparation, biological material and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116898988A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994447A (en) * | 2011-09-13 | 2013-03-27 | 谌兵来 | Method for culturing amplified human hair follicle stem cells and reprogramming amplified human hair follicle stem cells to induced pluripotent stem cells |
| CN103785064A (en) * | 2013-08-26 | 2014-05-14 | 济南磐升生物技术有限公司 | Method for regenerating human intact skin tissue by use of in vitro cultured cells |
| CN104630136A (en) * | 2013-11-15 | 2015-05-20 | 中国科学院广州生物医药与健康研究院 | Method for preparing induced pluripotent stem cells as well as composition used in method and application of composition |
| CN108384759A (en) * | 2018-01-16 | 2018-08-10 | 深圳市瑞亚再生医学科技有限责任公司 | The method and its application of induced skin fibroblast reprogramming |
| CN113453702A (en) * | 2018-09-28 | 2021-09-28 | 哈佛大学的校长及成员们 | Cell reprogramming to reverse senescence and promote tissue and tissue regeneration |
| CN116426573A (en) * | 2023-04-14 | 2023-07-14 | 臻赫医药(杭州)有限公司 | Reprogramming factor anti-aging expression system, biological material and application |
| CN116474120A (en) * | 2023-04-03 | 2023-07-25 | 臻赫医药(杭州)有限公司 | Reprogramming factor anti-aging mRNA composition, preparation method and application |
-
2023
- 2023-08-15 CN CN202311028818.XA patent/CN116898988A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994447A (en) * | 2011-09-13 | 2013-03-27 | 谌兵来 | Method for culturing amplified human hair follicle stem cells and reprogramming amplified human hair follicle stem cells to induced pluripotent stem cells |
| CN103785064A (en) * | 2013-08-26 | 2014-05-14 | 济南磐升生物技术有限公司 | Method for regenerating human intact skin tissue by use of in vitro cultured cells |
| CN104630136A (en) * | 2013-11-15 | 2015-05-20 | 中国科学院广州生物医药与健康研究院 | Method for preparing induced pluripotent stem cells as well as composition used in method and application of composition |
| CN108384759A (en) * | 2018-01-16 | 2018-08-10 | 深圳市瑞亚再生医学科技有限责任公司 | The method and its application of induced skin fibroblast reprogramming |
| CN113453702A (en) * | 2018-09-28 | 2021-09-28 | 哈佛大学的校长及成员们 | Cell reprogramming to reverse senescence and promote tissue and tissue regeneration |
| CN116474120A (en) * | 2023-04-03 | 2023-07-25 | 臻赫医药(杭州)有限公司 | Reprogramming factor anti-aging mRNA composition, preparation method and application |
| CN116426573A (en) * | 2023-04-14 | 2023-07-14 | 臻赫医药(杭州)有限公司 | Reprogramming factor anti-aging expression system, biological material and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kurita et al. | In vivo reprogramming of wound-resident cells generates skin epithelial tissue | |
| ES2634705T3 (en) | Identification of cell surface antigens, associated with tumor for diagnosis and therapy | |
| CN104840371B (en) | mesenchymal stem cell extract and use thereof | |
| Ouji et al. | Effects of Wnt-10b on hair shaft growth in hair follicle cultures | |
| Wu et al. | Comparison of mitochondrial transplantation by using a stamp-type multineedle injector and platelet-rich plasma therapy for hair aging in naturally aging mice | |
| Bawden et al. | A unique type I keratin intermediate filament gene family is abundantly expressed in the inner root sheaths of sheep and human hair follicles | |
| JP2009538854A (en) | Isolated natural natural collagen | |
| Thibeault et al. | Instability of extracellular matrix gene expression in primary cell culture of fibroblasts from human vocal fold lamina propria and tracheal scar | |
| Kalgudde Gopal et al. | Wound infiltrating adipocytes are not myofibroblasts | |
| CN108967358A (en) | A kind of construction method of zebra fish FL tumor model and its application | |
| CN116898988A (en) | Skin reprogramming factor preparation, biological material and application | |
| AU740340B2 (en) | Gene therapy vehicle comprising dermal sheath tissue | |
| Shimizu‐Nishikawa et al. | Hormonal regulation of adult type keratin gene expression in larval epidermal cells of the frog Xenopus laevis | |
| US8334136B2 (en) | Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor | |
| CN112190531B (en) | Anti-cell-aging preparation, preparation method and application thereof, cell and construction method thereof | |
| US20020146401A1 (en) | Generation and use of signal-plexes to develop specific cell types, tissues and/or organs | |
| Schembri et al. | Plucked human hair shafts and biomolecular medical research | |
| CN104673831B (en) | A kind of method and its application of maintenance and recovery human hair papilla cell primitiveness | |
| Geithe et al. | Isolation of a homogeneous morphogenetic factor, inducing mesoderm and endoderm derived tissues in Triturus ectoderm | |
| Sandoval et al. | Applications of Human Pluripotent Stem Cell–Derived Skin Organoids in Dermatology | |
| WO2019192453A1 (en) | Method of screening for active substance regulating skin pigmentation and application thereof | |
| Zhu et al. | Establishment of dermal sheath cell line from cashmere goat and characterizing cytokeratin 13 as its novel biomarker | |
| Bertolino et al. | In vitro biosynthesis of mouse hair keratins under the direction of follicular RNA | |
| CN116870197A (en) | Protissue cell proliferation reprogramming factor preparation and application | |
| Tsonis et al. | Specific expression of homoeobox-containing genes during induced differentiation of embryonal carcinoma cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |